Kornimate/medical-research-clean huggingface dataset:
the efficacy of the alcooquizz app to reduce hazardous alcohol consumption

Conditions: Alcohol Consumption

Summary: new technologies offer potential ways to provide and deliver preventative interventions. with respect to unhealthy alcohol use, offering people tools to assess and manage their risk at any given time using their smartphone may represent an additional opportunity to disseminate preventative interventions. nevertheless, there is a lack of knowledge on the acceptability and efficacy of smartphone applications for unhealthy alcohol use. alcooquizz, a smartphone app, has been previously evaluated using a before/after design without randomization, with participants reporting reductions in drinking over time. the current trial proposes to conduct an rct, comparing reductions in alcohol consumption between participants provided access to alcooquizz to a no intervention control. participants will be recruited through amazon's mturk crowdsourcing platform. potential participants identified as problem drinkers based on an initial survey will be invited to complete another survey in 6 months time. those who agree to be followed-up will be randomized to be provided a link to download the alcooquizz app or to a no link control condition. at six-months post-baseline, the mturk portal will be used to send invitation emails that contain a link to the follow-up survey that asks about their drinking and their impressions of the app. the primary hypothesis to be tested is that participants receiving access to the alcooquizz app will report a greater level of reduction in number of drinks in a typical week between the baseline survey and six-month follow-up as compared to participants in the no information control condition.


Eligibility criteria:
inclusion criteria: * 18 years of age or over * a score of 8 or over on the alcohol use disorders identification test (audit) * typically consumes 15 or more drinks per week, * willingness to complete a 6-month follow-up survey exclusion criteria: -
investigating muscle training's respiratory outcomes and voice enhancement in parkinson's disease

Conditions: Parkinson Disease; Pulmonary Disease; Voice Disorders

Summary: this study aims to investigate the effects of different types of respiratory muscle training on lung function, diaphragm movement, and voice quality in patients with parkinson's disease (pd). pd often leads to breathing difficulties and voice abnormalities due to weakened respiratory muscles and reduced diaphragm mobility. the study will involve 45 participants with pd, randomly assigned to three groups: one group will perform inspiratory muscle training, the second group will perform both inspiratory and expiratory muscle training, and the third group will receive placebo-controlled expiratory muscle training. the hypothesis is that targeted respiratory muscle training will significantly improve pulmonary function, diaphragm excursion, and phonatory measures compared to the placebo group. the findings aim to develop effective rehabilitation strategies to enhance the quality of life and communication abilities in individuals with pd.

this study aims to investigate the effects of respiratory muscle training on pulmonary function, diaphragm excursion, and phonatory measures in patients with parkinson's disease (pd). pd often leads to weakened respiratory muscles, reduced diaphragm movement, and voice abnormalities, impacting breathing and communication. the study will recruit 45 patients with pd, who will be randomly assigned to three groups: an inspiratory muscle training group, a combined inspiratory and expiratory muscle training group, and a placebo-controlled expiratory muscle training group. over eight weeks, participants will perform daily training sessions, with the intensity of the exercises adjusted periodically. assessments will include pulmonary function tests, ultrasound measurements of diaphragm thickness and movement, and various phonatory evaluations. the hypothesis is that respiratory muscle training will significantly improve respiratory and phonatory functions in pd patients compared to placebo, providing insights into effective rehabilitation strategies for enhancing their quality of life and communication abilities.

Eligibility criteria:
inclusion criteria: * patients with parkinson's disease (hoehn \& yahr stage i-iii), * patients aged 30-85 * patients with stable medical condition, regular medication adherence, and ability to follow instructions. exclusion criteria: * patients with cognitive impairment * patients with respiratory or other neurological diseases * patients with smoking history * patients with respiratory complications * patients with recent chest/abdominal surgery * patients with clinical instability * patients who are unable to perform pulmonary function tests correctly

Keywords: parkinson's disease pulmonary function respiratory muscle training diaphragm
a study to evaluate changes in hair in adult participants taking oral oriahnn capsules with heavy menstrual bleeding (hmb) associated with uterine fibroids (uf)

Conditions: Uterine Fibroids (UF)

Summary: uterine fibroids (uf) are benign smooth muscle neoplasms of the uterus that affect women of reproductive age. ufs are one of the leading causes of hospitalizations for gynecological disorders and often lead to hysterectomy. in this study, women with heavy menstrual bleeding (hmb) due to uf who are being treated with oriahnn will be followed to establish the incidence rate, time to onset, extent, pattern, and resolution of meaningful hair loss, as well as any racial differences. oriahnn is an approved drug for the management of hmb associated with uf. all study participants will receive oriahnn as prescribed by their study doctor in accordance with approved local label. study participants will be followed for up 24 months (part 1). approximately 1600 participants aged 18-50 years will be enrolled at 1 site in the united states. participants will receive oral oriahnn as prescribed by their physician according to their routine clinical practice and local label. participants will be followed for 24 months. there is expected to be no additional burden for participants in this trial. participants will complete questionnaires on a quarterly basis.


Eligibility criteria:
inclusion criteria: part 1: * international classification of disease-10 (icd-10) diagnosis codes for both uterine fibroids (uf) (d25.x) and heavy menstrual bleeding (hmb), defined as menorrhagia (n92.0, n92.4) or menometrorrhagia (n92.1) in the electronic health record (ehr) system. * plans to initiate or has initiated oriahnn treatment within 14 days of study enrollment. * able to provide photographs of their scalp within 14 days of oriahnn initiation, based on instruction provided. part 2: - changes in thickness, fullness or pattern of hair that results in less hair than normal, or hair shedding that is increased from normal in the hair questionnaire. exclusion criteria: * current or history of hair thinning, hair loss, or alopecia (defined as physician-diagnosed or patient-reported hair loss). * have a contraindication to receive oriahnn per prescribing information. * any of the following occurrences within 180 days prior to oriahnn prescription. * prescription for oriahnn, another gonadotropin releasing hormone (gnrh) antagonist \[including myfembree (relugolix, estradiol/norethindrone acetate\]) or gnrh agonist. * pregnancy/childbirth. * new diagnosis of thyroid disease. * new diagnosis of inflammation or infection of the scalp (e.g., psoriasis, tinea capitis). * have taken medications or undergone therapies that may cause alopecia, hair loss, or both. this includes but is not limited to chemotherapy, checkpoint inhibitors, epidermal growth factor antagonists, or radiation anywhere on the body. * initiation or changes in medications or doses for the management of thyroid diseases * any other medical condition or surgery requiring hospitalization (other than uf)

Keywords: uterine fibroids (uf) heavy menstrual bleeding (hmb) oriahnn elagolix estradiol norethindrone acetate
patient reported outcome measures for ablation of cardiac arrhythmias

Conditions: Cardiac Arrhythmia

Summary: a multicentre, prospective observational study to develop, evaluate and validate patient reported outcome measures (proms) for patients treated with cardiac ablation for symptomatic cardiac arrhythmias

this study aims to develop, evaluate and validate disease specific proms for patients in the uk treated with cardiac ablation for cardiac arrhythmias. the potential benefits include support for clinicians to improve their performance, assisting patients in making informed choices and strengthening audit and research. phase 1 of the study will involve patient interviews with approximately 30 patients from 2 sites. these, together with input from a multidisciplinary team, will aim to improve drafts of disease specific questionnaires. this will be followed by phase 2 which will trial the questionnaires in a group of approximately 600 patients from three sites. in phase 2 patients will be asked to complete a pre-procedure questionnaire relating to their symptoms, quality of life and procedure expectations. they will also be sent post-procedure questionnaires relating to procedural outcomes, symptoms and quality of life at 8-16 weeks post procedure and at 1 and 5 years post-procedure. the responses obtained from these proms will be used to undertake recommended statistical tests of reliability and validity.

Eligibility criteria:
inclusion criteria: * patients with symptomatic cardiac arrhythmias * consented to and awaiting a cardiac ablation procedure * able to read, write and understand english or welsh * capable of giving informed written consent exclusion criteria: * not able to read, write and understand english or welsh * not able to provide informed written consent

Keywords: patient reported outcome measures proms cardiac arrhythmia cardiac ablation
a clinical trial of metformin to decrease glucocorticoids side effects in patients with autoimmune uveitis

Conditions: Uveitis; Metformin; Glucocorticoid

Summary: this project is designed to evaluating the use of combination therapy of glucocorticoid and metformin to decrease glucocorticoid side effects in participants with autoimmune uveitis.this study also aims to evaluate the anti-inflammatory and immunosuppressive effects of combination therapy.

approval of the study was obtained from the hospital's ethical committee. the study design and methodology followed the tenets of declaration of helsinki. all participants were provided with written informed consent and received a thorough explanation of the study design, aims, and the side effect of metformin. this is a multicenter, randomized, controlled clinical trial research. according to 1:1 ratio, all participants are randomly divided into two groups, the metformin group and placebo group. according to the fasting blood glucose (fbg), triglycerides (tg),total cholesterol (tc) and body mass index (bmi), the investigators compared experimental group with control group to evaluate whether the use of combination therapy of glucocorticoid and metformin decrease glucocorticoid side effects in participants with autoimmune uveitis. according to best corrected visual acuity (bcva), anterior chamber and vitreous inflammation, fluorescence fundus angiography (ffa), electroretinogram (erg) and so on, the investigators evaluate the anti-inflammatory and immunosuppressive effects of metformin in treatment of autoimmune uveitis.

Eligibility criteria:
inclusion criteria: 1. attending tianjin medical university eye hospital, ophthalmology department of peking union medical college hospital, ophthalmology department of peking university first hospital and zhongshan ophthalmic center sun yat-sen university from january 2018 to january 2022. 2. chronic and non-infectious autoimmune uveitis with systemic glucocorticoids treatment (initiation dosage ≥ 1 mg/kg/d or ≥ 50 mg/d). 3. fbg \< 6.1 mmol/l, hbalc\<6.o%, tc \<6.2 mmol/l(240 mg／d1) and tg \<2.3 mmol/l(200 mg／dl). 4. all genders, age ≥ 18 years old. 5. ready for systemic glucocorticoids treatment. 6. willing to follow all study requirements and sign the informed consent. 7. without history of cancer and serious systemic diseases. exclusion criteria: 1. participate in other clinical trials within the preceding one years 2. planning ophthalmologic surgery over the next three months. 3. with other sight-threatening diseases except cataract, such as glaucoma, diabetic retinopathy, retinal detachment, and so on. 4. taking or will take immunosuppressants which affecting glycometabolism and lipid metabolism except methotrexate,mycophenolate and azathioprine. 5. any known history of a serious infection (e.g., hiv, hepatitis, pneumonia, syphilis or tuberculosis). 6. any known history of diabetes mellitus, severe hepatic, renal or heart disease. 7. any known history of drug addiction, drug abuse and malignant tumor. 8. presence of a transplanted solid organ. 9. pregnant women and nursing mothers. 10. any known history of mental disorders.
role of nutritional intervention in critically ill child

Conditions: Nutrition Disorder, Child

Summary: * assess the nutritional status of critically ill children using different nutritional assessment tools in management. * assess accuracy and validity of screening tools in diagnosis of malnutrition by the following: * strong kids * stamp * pyms * assess the effect of early versus late enteral nutrition on the outcome and predict the complication associated with enteral feeding.

malnutrition affects millions of children throughout the world. according to espen nutritional risk screening tools have been designed to detect protein and energy under nutrition and predict if under nutrition may develop or worsen. the screening was validated tool for assessment of malnutrition in pediatrics (stamp) that evaluates patient's clinical diagnosis, nutritional intake during hospitalization and anthropometric measurements, developing a care plan based on the child's overall malnutrition risk. the screening tool for impaired nutritional status and growth (strong kids) consists of four items: clinical assessment, high-risk diseases, nutritional intake and losses, weight loss or poor weight gain. the pediatric yorkhill malnutrition score (pyms) is adopted among patients between 1 and 16 years of age assesses four items: bmi, history of recent weight loss, changes in nutritional intake and the expected effect of current medical condition on patient's nutritional status. indirect calorimetry, calculated from analysis of the inspired and expired gases, is the best method for evaluating individual energy expenditure. protein requirements are highe. the catabolic effects of illness lead to negative nitrogen balance. randomized protein-supplemented enteral diet achieved 3.1g/kg/day protein and positive nitrogen balance by picu day 5. enteral nutrition is more physiological, simpler, can be started more quickly and cheaper, it does not require special preparation, and it can be started and modified at any time. par enteral nutrition has reserved for those patients with intestinal obstruction or severe gastrointestinal damage, ischemia, inflammation, hemorrhage, peritonitis and paralytic ileus.

Eligibility criteria:
inclusion criteria: * critically ill children aged 1-5 years admitted to picu. exclusion criteria: * infants before the age of one year and children after the age of five years. * any child with chronic illness. * patients with multiorgans failure. * children with congenital anomalies. * children on renal dialysis.
sternal wound and aortic graft (swag), an observational cohort study.

Conditions: Surgical Site Infection; Sternal Wound Infection

Summary: the aim of this study is to systematically explore the perioperative presence of p acnes in all layers of sternal wound incision as well as contamination of graft material and prosthetic valves during primary operation. secondly, to compare if different regimes of antibiotics affects the bacterial growth. cultures will be taken from the skin, subcutaneous, and from the implanted valve prostheses with a rayon swab.graft and felt material will, after being pressed subcutaneous for 15 sec, placed into prepared sterile bottles containing broth for aerobe and anaerobe cultures. surgical gloves will be cultured.


Eligibility criteria:
inclusion criteria: * open cardiac surgery; coronary artery bypass grafting, valve replacement/repair or a combination of these. exclusion criteria: * skin conditions such as eczema, psoriasis. * revision surgery * aortic surgery
effects of tens therapy following arthroscopic knee surgery

Conditions: Meniscus Tear

Summary: following standard of care procedures for arthroscopy knee surgery it is anticipated that transcutaneous electrical nerve stimulation (tens) will provide improved pain relief and improve functional outcomes.


Eligibility criteria:
inclusion criteria: * age 18-60 * bmi\<50 * no significant joint malalignment * no significant ligamentous instability * no significant radiographic joint space narrowing * no prior significant knee surgery * unilateral knee surgery * not workman's compensation * planned knee arthroscopy for meniscectomy, chondroplasty or synovectomy exclusion criteria: * age \ 60 * bmi \> 50 * significant joint malalignment * significant ligamentous instability * significant radiographic joint space narrowing * prior significant knee surgery * bilateral knee surgery planned * worker's compensation * no planned knee arthroscopy for menisectomy, chondroplasty or synovectomy
treating drug-resistant childhood schizophrenia

Conditions: Schizophrenia

Summary: this study will compare clozapine and olanzapine (zyprexa®) for the treatment of children and adolescents who have failed standard antipsychotic treatment for schizophrenia.

schizophrenia is a devastating illness regardless of the age at which it presents. when this disorder occurs in childhood or adolescence, the consequences in terms of functional impairment, loss of developmental opportunities, and family and societal burden are particularly dramatic. evidence supports the improved efficacy and/or side effect profile of atypical antipsychotic medication in adults. thus, it is essential to examine whether the potential benefits of these agents can be extended to children, particularly children who have failed standard treatment. patients are randomly assigned to receive either clozapine or olanzapine daily for 12 weeks. patients meet with the study team once a week to discuss progress and record side effects. three parent meetings take place during the study. during these meetings, questions are discussed and support and education about schizophrenia are given to parents. various scales to measure psychotic, manic, aggressive, and depressive symptoms are used to assess patients.

Eligibility criteria:
inclusion criteria: * dsm-iv criteria for treatment-refractory schizophrenia or schizoaffective disorder * willingness to use an acceptable form of birth control, if applicable exclusion criteria: * neurological or medical disorders that would contraindicate treatment with clozapine or olanzapine * iq less than 70 * dsm-iv criteria for substance (other than caffeine or nicotine) related disorder * failure of an adequate trial of olanzapine or clozapine
discovering factors in cervical cancer patients' clinical trial experiences

Conditions: Cervical Cancer

Summary: the percentages of participants in clinical studies haven't always been perfectly representative of a particular group. this research examines the variables that affect a patient's choice to enroll in, discontinue participation in, or resume participation in a clinical trial for cervical cancer. it will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future cervical cancer studies.


Eligibility criteria:
inclusion criteria: * aged ≥ 18 years old * ability to understand and the willingness to sign a written informed consent document. * willing and able to comply with scheduled visits, treatment schedule, laboratory tests and other requirements of the study. exclusion criteria: * is pregnant, breastfeeding or expecting to conceive within the projected duration of the study * any mental or medical condition that prevents the patient from giving informed consent or participating in the trial * patients with any significant history of non-compliance to medical regimens or with inability to grant a reliable informed consent.

Keywords: cervical cancer
monthly replacement orthokeratology for myopia control in young children

Conditions: Myopic Progression

Summary: the two-year prospective study aims at investigating frequently replacement effect on myopia control in young children, and the use of weekly protein removal system in monthly replacement modality orthokeratology lenses on surface deposit.

in this two-year prospective study, low myopic children, aged 6-8 years, who have no prior experience in contact lens wear and myopia control treatment will be recruited. they will be prescribed with monthly replacement orthokeratology lenses for a period of one year. axial elongation and ocular conditions during the study will be determined. subjects will be randomly assigned to normal cleaning and intensive cleaning groups. subjects in normal cleaning group will be provided with complimentary contact lenses solutions for daily cleaning and disinfection. in addition to the daily procedures for lens case, subjects in the intensive cleaning group will be required to perform weekly protein removal.

Eligibility criteria:
inclusion criteria: * aged 6-10 years * normal ocular and general condition and not on medication which may contraindicate ortho-k lens wear * refractive sphere between -0.75 to -4.00 d, refractive cylinder ≤ -1.50 d and anisometropia ≤ -1.00 d * best correctable vision better than 0.08 logmar in the worse eye * normal binocular function and accommodative status * no prior experience in contact lens wear and myopia control treatment exclusion criteria: * strabismus at distance or near * contraindication for ortho-k lens wear * prior history of ocular surgery, trauma, or chronic ocular disease * systemic or ocular conditions that may interfere refractive development * systemic or ocular conditions that may interfere tear quality and contact lens wear * poor response to the use of study lenses * poor compliance to test procedures * poor compliance to the use of ortho-k lenses (e.g. use of solution, use of lenses) * poor compliance to follow-up schedule

Keywords: myopia progression orthokeratology replacement modality surface deposits
nosocomial influenza surveillance 2018 - 2022

Conditions: Hospital-Acquired Infection; Influenza

Summary: hospital-acquired influenza is associated with significant morbidity and mortality in hospitalized patients notably elderly patients. furthermore, it is also associated with a large economic impact for the hospitals. the transmission of influenza has been mostly reported in pediatric and long-stay units. the chains of transmission of influenza in acute-stay units have to be describe in order to prevent and control potential outbreaks. furthermore, to know clinical symptoms seems to be important in order to identify potential sources of virus as soon as possible and to set up appropriate hygiene prevention measures. moreover, the definition of the hospital-acquired influenza has to be harmonized for all over the studies, especially concerning the delay between the admission in the hospital and the symptoms onset. the aim of this study is to describe the hospital-acquired influenza in a french university hospital of around 800 beds


Eligibility criteria:
inclusion criteria: * adult patients and health-care workers in a participating unit in the study, * more than 18 years old, * volunteers, * who present an influenza-like illness defined by fever \> 37,8°c or/and cough or sore throat. exclusion criteria: -everyone who does not present the inclusion criteria.